Author

Ashley K. Koegel

Observed names: Ashley K Koegel, Ashley Koegel, Koegel, Ashley, Koegel, Ashley K.

Observed institutions: Boston Children's Hospital, Howard Hughes Medical Institute, University of California, Los Angeles, University of California, San Francisco, Friedrich-Alexander-Universität Erlangen-Nürnberg, Bristol-Myers Squibb (United States), UCSF Benioff Children's Hospital, Stanford Medicine, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, UCSF Helen Diller Family Comprehensive Cancer Center, Stanford University

OpenAlex ID: A5028539100

Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters

2011 · Tiffany Hung, Yulei Wang, et al. · Nature Genetics · 1,165

PDF

Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies

2020 · Ruth Dannenfelser, Gregory M. Allen, et al. · Cell Systems · 107

PDF

RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis

2010 · Juliana J. Oh, Eileen O. Taschereau, et al. · Lung Cancer · 42

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

2022 · Luciano J. Costa, Shaji K Kumar, et al. · Blood · 38

Fusion driven JMML: a novel CCDC88C–FLT3 fusion responsive to sorafenib identified by RNA sequencing

2019 · Alexander K. Chao, Julia A. Meyer, et al. · Leukemia · 38

Acute lymphoblastic leukemia in a patient with MonoMAC syndrome/GATA2 haploinsufficiency

2016 · Ashley K. Koegel, Inga Hofmann, et al. · Pediatric Blood & Cancer · 28

Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma

2025 · Gayathri Ravi, Shambavi Richard, et al. · Leukemia · 14

PDF

The two single nucleotide polymorphisms in the H37/RBM5 tumour suppressor gene at 3p21.3 correlated with different subtypes of non-small cell lung cancers

2007 · Juliana J. Oh, Ashley K. Koegel, et al. · Lung Cancer · 12

Case report: Impact of BITE on CAR ‐T cell expansion

2019 · Haneen Shalabi, Ashley Koegel, et al. · Advances in Cell and Gene Therapy · 11

PDF

Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung cancer tumor suppressor locus

2007 · Juliana J. Oh, Baher N. Boctor, et al. · Human Genetics · 9

Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspective

2025 · Elena W Y Hsieh, James B Chung, et al. · RMD Open · 5

PDF

Repurposing mebendazole against triple-negative breast cancer CNS metastasis

2024 · Adrian J. Rodrigues, Sophia B. Chernikova, et al. · Journal of Neuro-Oncology · 5

PDF

Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies

2024 · Fabian Mueller, Krish Patel, et al. · Blood · 4

PDF

Acute Lymphoblastic Leukemia in a Patient with Monomac Syndrome/GATA2 Haploinsufficiency

2015 · Ashley Koegel, Venee N. Tubman, et al. · Blood · 3

P105 NEX-T CD19 chimeric antigen receptor (CAR) T-cell therapy CC-97540 (BMS-986353): Preclinical and translational evidence of deep B-cell depletion suitable for study in severe refractory autoimmune diseases

2024 · Georg Schett, Tatyana Feldman, et al. · Poster presentations · 2

PDF

A Risk Stratified Treatment Algorithm for Patients with Juvenile Myelomonocytic Leukemia

2017 · Ashley Koegel, Elliot Stieglitz · The Hematologist · 2

Pregnancies in Patients with Autoimmune Disease Receiving CAR T-Cell Therapy

2026 · Georg Schett, Andreas Wirsching, et al. · New England Journal of Medicine

OC.57 Safety and efficacy of CD19 NEX-T® (BMS-986353), a chimeric antigen receptor (CAR) T cell therapy, in systemic sclerosis (SSc): findings from the breakfree-1 trial

2026 · Dinesh Khanna, David S Korman, et al.

Nex-T TM Cluster of Differentiation 19 (CD19) Chimeric Antigen Receptor (CAR) T-Cell Therapy BMS-986353 (CC-97540): Comparative Analysis of Baseline Patient Data from Trials in Systemic Lupus Erythematosus (SLE) and Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Related to Manufacturability and Potential Safety

2023 · Fabian Mueller, Julie Rytlewski, et al. · Blood

PDF

Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters

2021 · Wong, David J., Børresen-Dale, Anne Lise, et al. · UNC Libraries

Pregnancies in Patients with Autoimmune Disease Receiving CAR T-Cell Therapy.

· Schett, Georg, Wirsching, Andreas, et al. · Open Access CRIS of the University of Bern

Works count: 21

Citation count: 1,484

H-index: 9

I10-index: 9